76 related articles for article (PubMed ID: 19764482)
1. [Positron emission tomography: contribution to diagnosis of dementia and development of disease-modifying drugs].
Ito K; Kato T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Aug; 29(4):153-60. PubMed ID: 19764482
[TBL] [Abstract][Full Text] [Related]
2. [Current and future prospects of nuclear medicine in dementia].
Ito K; Inui Y; Kizawa T; Kimura Y; Kato T
Rinsho Shinkeigaku; 2017 Sep; 57(9):479-484. PubMed ID: 28804110
[TBL] [Abstract][Full Text] [Related]
3. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.
Foster NL; Wang AY; Tasdizen T; Fletcher PT; Hoffman JM; Koeppe RA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S29-36. PubMed ID: 18631997
[TBL] [Abstract][Full Text] [Related]
4. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
[TBL] [Abstract][Full Text] [Related]
5. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments.
Reiman EM;
Neurobiol Aging; 2011 Dec; 32 Suppl 1(Suppl 1):S44-7. PubMed ID: 21983241
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography imaging in dementia.
Herholz K; Carter SF; Jones M
Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
[TBL] [Abstract][Full Text] [Related]
7. Visual assessment versus quantitative three-dimensional stereotactic surface projection fluorodeoxyglucose positron emission tomography for detection of mild cognitive impairment and Alzheimer disease.
Lehman VT; Carter RE; Claassen DO; Murphy RC; Lowe V; Petersen RC; Peller PJ
Clin Nucl Med; 2012 Aug; 37(8):721-6. PubMed ID: 22785496
[TBL] [Abstract][Full Text] [Related]
8. Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework.
Garibotto V; Herholz K; Boccardi M; Picco A; Varrone A; Nordberg A; Nobili F; Ratib O;
Neurobiol Aging; 2017 Apr; 52():183-195. PubMed ID: 28317648
[TBL] [Abstract][Full Text] [Related]
9. Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early alzheimer disease in patients of a memory clinic.
Scheurich A; Muller MJ; Siessmeier T; Bartenstein P; Schmidt LG; Fellgiebel A
Dement Geriatr Cogn Disord; 2005; 20(5):271-7. PubMed ID: 16158009
[TBL] [Abstract][Full Text] [Related]
10. FDG-PET in early AD diagnosis.
Chew J; Silverman DH
Med Clin North Am; 2013 May; 97(3):485-94. PubMed ID: 23642583
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.
Mosconi L; Tsui WH; Pupi A; De Santi S; Drzezga A; Minoshima S; de Leon MJ
J Nucl Med; 2007 Jul; 48(7):1129-34. PubMed ID: 17574982
[TBL] [Abstract][Full Text] [Related]
12. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease.
Foster NL; Heidebrink JL; Clark CM; Jagust WJ; Arnold SE; Barbas NR; DeCarli CS; Turner RS; Koeppe RA; Higdon R; Minoshima S
Brain; 2007 Oct; 130(Pt 10):2616-35. PubMed ID: 17704526
[TBL] [Abstract][Full Text] [Related]
13. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
14. Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis.
Mosconi L; Tsui WH; De Santi S; Li J; Rusinek H; Convit A; Li Y; Boppana M; de Leon MJ
Neurology; 2005 Jun; 64(11):1860-7. PubMed ID: 15955934
[TBL] [Abstract][Full Text] [Related]
15.
Burrell LD; Holley D
J Nucl Med Technol; 2018 Jun; 46(2):151-152. PubMed ID: 29273694
[TBL] [Abstract][Full Text] [Related]
16. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET.
Drzezga A; Grimmer T; Riemenschneider M; Lautenschlager N; Siebner H; Alexopoulus P; Minoshima S; Schwaiger M; Kurz A
J Nucl Med; 2005 Oct; 46(10):1625-32. PubMed ID: 16204712
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography diagnosis of Alzheimer's disease.
Coleman RE
Neuroimaging Clin N Am; 2005 Nov; 15(4):837-46, x. PubMed ID: 16443494
[TBL] [Abstract][Full Text] [Related]
18. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?
Jagust W; Reed B; Mungas D; Ellis W; Decarli C
Neurology; 2007 Aug; 69(9):871-7. PubMed ID: 17724289
[TBL] [Abstract][Full Text] [Related]
19. Comparison study of amyloid PET and voxel-based morphometry analysis in mild cognitive impairment and Alzheimer's disease.
Waragai M; Okamura N; Furukawa K; Tashiro M; Furumoto S; Funaki Y; Kato M; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol Sci; 2009 Oct; 285(1-2):100-8. PubMed ID: 19552926
[TBL] [Abstract][Full Text] [Related]
20. Signs and Artifacts in Amyloid PET.
Lundeen TF; Seibyl JP; Covington MF; Eshghi N; Kuo PH
Radiographics; 2018; 38(7):2123-2133. PubMed ID: 30422768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
